株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

野兎病:パイプライン製品の分析

Tularaemia - Pipeline Review, H1 2017

発行 Global Markets Direct 商品コード 293888
出版日 ページ情報 英文 68 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.79円で換算しております。
Back to Top
野兎病:パイプライン製品の分析 Tularaemia - Pipeline Review, H1 2017
出版日: 2017年05月23日 ページ情報: 英文 68 Pages
概要

野兎病(ツラレミア)は、野兎病菌(Francisella tularensis)と呼ばれる細菌に起因する感染症です。主に節足動物(特にダニや蚊)に咬まれることで感染します。皮膚、結膜嚢、口腔咽頭粘膜を介して、感染した動物や動物性物質との直接接触、汚染された食品や水の摂取、汚染されたほこりやエアロゾルの吸入によって感染します。症状は、皮膚潰瘍、リンパ腺の腫れや痛み、発熱、悪寒などです。治療には、抗生物質や健康的な生活スタイルが推奨されています。

当レポートでは、野兎病に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

野兎病の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Aradigm Corporation
  • Arno Therapeutics, Inc.
  • DynPort Vaccine Company LLC
  • Emergent BioSolutions Inc.
  • EpiVax, Inc.
  • Grifols, S.A.
  • Merck & Co., Inc.
  • Tetraphase Pharmaceuticals Inc.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与法別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC9334IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H1 2017, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.

Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tularaemia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 2 and 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Tularaemia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tularaemia (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tularaemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tularaemia (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tularaemia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tularaemia (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tularaemia (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tularaemia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Tularaemia - Overview
  • Tularaemia - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Tularaemia - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tularaemia - Companies Involved in Therapeutics Development
  • Aradigm Corp
  • Arno Therapeutics Inc
  • DynPort Vaccine Company LLC
  • Emergent BioSolutions Inc
  • EpiVax Inc
  • Grifols SA
  • Merck & Co Inc
  • Tetraphase Pharmaceuticals Inc
  • Tularaemia - Drug Profiles
  • AR-12 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ARD-3100 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ARD-3150 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ciprofloxacin hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EV-035 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Infectious Diseases - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • solithromycin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SRI-011225 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TP-271 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tularaemia [strain A] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tularaemia [strain B] vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tularaemia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tularemia vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tularaemia - Dormant Projects
  • Tularaemia - Discontinued Products
  • Tularaemia - Product Development Milestones
  • Featured News & Press Releases
  • Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015
  • May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12
  • Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Tularaemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Tularaemia - Pipeline by Aradigm Corp, H1 2017
  • Tularaemia - Pipeline by Arno Therapeutics Inc, H1 2017
  • Tularaemia - Pipeline by DynPort Vaccine Company LLC, H1 2017
  • Tularaemia - Pipeline by Emergent BioSolutions Inc, H1 2017
  • Tularaemia - Pipeline by EpiVax Inc, H1 2017
  • Tularaemia - Pipeline by Grifols SA, H1 2017
  • Tularaemia - Pipeline by Merck & Co Inc, H1 2017
  • Tularaemia - Pipeline by Tetraphase Pharmaceuticals Inc, H1 2017
  • Tularaemia - Dormant Projects, H1 2017
  • Tularaemia - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Tularaemia, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top